51 research outputs found
Employment survival of nursing workers in a public hospital
This study aimed at estimating the employment "survival" time of nursing workers after their admission to a public hospital as a turnover index. The Life Table method was used in order to calculate the employment survival probability by X years for each one of the categories of workers. The results showed an accentuated turnover of the work force in the studied period. The categories nursing auxiliary and nurse presented low stability in employment while the category nursing technician was more stable.El presente trabajo mide el tiempo de "sobrevivencia" en el empleo de los trabajadores de enfermerĂa, despuĂ©s de su admisiĂłn en un hospital pĂşblico, como uno de los indicadores de rotaciĂłn. Se utilizĂł la tĂ©cnica de la Tabla de vida de seguimiento para calcular la probabilidad de sobrevivencia en el empleo por X años para cada una de las categorĂas de trabajadores. Los resultados mostraron, para el periodo estudiado, una rotaciĂłn acentuada de esa fuerza de trabajo. Las categorĂas, auxiliar de enfermerĂa y enfermero presentaron baja estabilidad en el empleo mientras que la categorĂa tĂ©cnico de enfermerĂa fue la más estable.O presente trabalho estima o tempo de "sobrevivĂŞncia" no emprego dos trabalhadores de enfermagem, apĂłs sua admissĂŁo em um hospital pĂşblico, como um dos indicadores de rotatividade. Utilizou-se a tĂ©cnica de Tábua de vida de seguimento para calcular a probabilidade de sobrevivĂŞncia no emprego por X anos para cada uma das categorias de trabalhadores. Os resultados apontaram, para o perĂodo estudado, uma rotatividade acentuada dessa força de trabalho. As categorias, auxiliar de enfermagem e enfermeiro apresentaram baixa estabilidade no emprego enquanto a categoria tĂ©cnico de enfermagem foi a mais estável
Average working life of nurses graduating from the University of SĂŁo Paulo at RibeirĂŁo Preto College of Nursing, Brazil
O objetivo deste estudo Ă© o de medir o tempo mĂ©dio de trabalho em saĂşde dos egressos da Escola de Enfermagem de RibeirĂŁo Preto da Universidade de SĂŁo Paulo no perĂodo de 1957 a 1990, totalizando 1112 diplomados. Trata-se de um estudo descritivo de corte transversal, sendo que os dados foram coletados no perĂodo de março de 1992 a fevereiro de 1993. Medindo o tempo de trabalho em saĂşde, usamos a tĂ©cnica denominada tábuas de sobrevivĂŞncia de uso comum nos estudos de seguimento. A partir de nossos dados podemos estimar que a vida mĂ©dia de labor vale por 18,12 anos.El objetivo de este estudio es el de medir el tiempo medio de trabajo en salud de los egresados de la Escuela de EnfermerĂa de RibeirĂŁo Preto de la Universidad de SĂŁo Paulo en el periodo de 1957 a 1990, totalizando 1112 egresados. Se trata de un estudio descriptivo de corte transversal, siendo que los datos fueron recolectados en el periodo de marzo de 1992 a febrero de 1993. Midiendo el tiempo de trabajo en salud, usamos la tĂ©cnica denominada tablas de sobrevivencia de uso comĂşn en los estudios de seguimiento. A partir de nuestros datos podemos estimar que la vida media productiva está en 18,12 años.This study aimed at measuring the average working time in health care of nurses graduating from the University of SĂŁo Paulo at RibeirĂŁo Preto College of Nursing, Brazil. This research includes 1,112 nurses who graduated from 1957 to 1990. It is a descriptive cross-sectional study. Data were obtained from March, 1992 to February, 1993. Statistical methods for survival data analysis were used. The average time was 18.12 years
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo
Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab
The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension
Pervasive gaps in Amazonian ecological research
Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4
While the increasing availability of global databases on ecological communities has advanced our knowledge
of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In
the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of
Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus
crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced
environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian
Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by
2050. This means that unless we take immediate action, we will not be able to establish their current status,
much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio
- …